Fierce Pharma

OCTOBER 5, 2023

Five weeks removed from slashing 25% of its workforce amid problems wi | Five weeks removed from slashing 25% of its workforce amid problems with its groundbreaking geographic atrophy drug, Apellis is making progress in re-accelerating the launch of Syfovre. Ahead of its quarterly earnings presentation, Apellis estimated sales of approximately $74 million for the third quarter for Syfovre and a rekindling of demand in recent weeks as doctors get a better handle on the risk of vascular retinitis.

Drugs 111

Drugs Doctor Doctors Sales 111

Bio Pharma Dive

OCTOBER 5, 2023

Kyowa will pay nearly $400 million to acquire Orchard, which sells the gene therapy Libmeldy in Europe but has struggled to find paths to market for other experimental treatments.

Gene Therapy 278

Gene Therapy Gene Marketing 278

Pharmaceutical Technology

OCTOBER 5, 2023

Lumicell co-founder, Moungi Bawendi, has been awarded the accolade alongside two others for his research into quantum dots.

Research 258

Research 258

Bio Pharma Dive

OCTOBER 5, 2023

The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.

Sales 277

Sales Drugs 277

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 5, 2023

Milk teas – a variety of sweet drinks including bubble tea – have become phenomenally popular in China and other parts of Asia in recent years, and a new study has highlighted some worrying links between the beverage and mental health issues.

Research 238

Research Clinical Trials Clinical Trials Clinical Research 238

Bio Pharma Dive

OCTOBER 5, 2023

The company exercised an option to buy Mitokinin, a Pfizer-backed drugmaker built on work by scientific co-founders Nicholas Hertz and Kevan Shokat.

Drugs 195

Drugs 195

Bio Pharma Dive

OCTOBER 5, 2023

Precede has used the money to develop a platform that reveals the activity of genes and pathways.

Gene 162

Gene Development 162

Pharmaceutical Technology

OCTOBER 5, 2023

Orchard's portfolio includes Libmeldy, which has been approved for a rare genetic disorder, metachromatic leukodystrophy.

Gene Therapy 162

Gene Therapy Gene Genetics 162

Bio Pharma Dive

OCTOBER 5, 2023

All told, the biotech said it will discontinue more than half of its research and technology projects, including a Parkinson’s disease treatment.

Research 162

Research 162

Rethinking Clinical Trials

OCTOBER 5, 2023

The GRACE trial, an NIH Pragmatic Trials Collaboratory Demonstration Project, was featured in a segment on CBS News Chicago. Co–principal investigator Ardith Doorenbos was interviewed for the segment as part of the news program’s observance of Sickle Cell Awareness Month. “Millions of people around the world with sickle cell disease really suffer from very serious chronic pain, which impacts all their life experiences,” Doorenbos said. “What the GRACE trial is doing is ta

Trials 147

Trials Clinical Trials Clinical Trials 147

Advertisement

Clinical Supply

Pharmaceutical Technology

OCTOBER 5, 2023

The US FDA has issued a draft guidance to aid sponsors in developing biologics and drugs for stimulant use disorders.

Development 147

Development Drugs 147

Pharma Times

OCTOBER 5, 2023

The research approach will help small- to mid-sized organisations to advance their clinical studies - News - PharmaTimes

Research 136

Research 136

Pharmaceutical Technology

OCTOBER 5, 2023

Antibody-drug conjugates (ADCs) saw a 400% growth in total licensing agreement deal value from 2017 to 2022 and reached a peak of $16.6bn.

Licensing 130

Licensing Licensing Antibody Drugs 130

Pharma Times

OCTOBER 5, 2023

It will be the company’s first platform to be installed in an external scientific setting - News - PharmaTimes

DNA 134

DNA Development 134

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharmaceutical Technology

OCTOBER 5, 2023

IMIDomics and WuXi Biologics have signed an agreement to advance the development and manufacturing of the humanised antibody, IMB1001

Antibody 130

Antibody Development Manufacturing 130

pharmaphorum

OCTOBER 5, 2023

Roche app relieves diabetes distress in clinical trial Phil.

Clinical Trials 125

Clinical Trials Clinical Trials Trials 125

Pharmaceutical Technology

OCTOBER 5, 2023

The initiative was created in partnership with Medicines Discovery Catapult, the Medical Research Council, and Innovate UK.

Medicine 130

Medicine Drugs Research 130

Fierce Pharma

OCTOBER 5, 2023

In Viatris' attempt to become the first company to reach the market with generic versions of Novo Nordisk’s diabetes and obesity juggernauts Ozempic and Wegovy, the company received good and bad ne | After hearing a petition from Viatris, the U.S. Patent and Trademark Office will conduct a review to determine the validity of a patent held by Novo Nordisk.

Marketing 125

Marketing 125

Advertisement

Clinical Supply

Pharmaceutical Technology

OCTOBER 5, 2023

Shorla Oncology has received $35m in Series B funding to boost the oncology portfolio growth by advancing its pipeline of drug candidates.

Drugs 130

Drugs 130

Fierce Pharma

OCTOBER 5, 2023

Merck’s Keytruda is riding a winning streak in bladder cancer. | Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in muscle-invasive urothelial carcinoma.

FDA Approval 124

FDA Approval Trials 124

Pharmaceutical Technology

OCTOBER 5, 2023

Advanz Pharma has signed an agreement to licence Dimerix’s DMX-200 for marketing in the UK, Australia and New Zealand among others.

Licensing 130

Licensing Licensing Drugs Marketing 130

Fierce Pharma

OCTOBER 5, 2023

Mirati Therapeutics enjoyed a stock-price spike Thursday after rumors started swirling about a potential buyout by French drug giant Sanofi. | Mirati Therapeutics saw its stock price spike Thursday at the possibility of a buyout from Sanofi. The French pharma has been evaluating a potential acquisition of the KRAS drug developer, Bloomberg reports, citing unnamed sources.

Drugs 124

Drugs Development 124

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Pharmaceutical Technology

OCTOBER 5, 2023

Inhibikase is planning a Phase II trial to investigate its Abelson Tyrosine Kinase inhibitor in MSA.

Drugs 130

Drugs Trials 130

Pharmaceutical Commerce

OCTOBER 5, 2023

In an interview at LogiPharma USA 2023 with Pharma Commerce Editor Nicholas Saraceno, Tracy Nasarenko, Sr. Director of Community Engagement for Pharmaceuticals, GS1 US highlights her “DSCSA—Final Checks to Have Before Deadlines.

124

124

Pharmaceutical Technology

OCTOBER 5, 2023

EMA gives positive opinion for granting Calliditas Therapeutics’ Alport syndrome drug an orphan designation.

Drugs 130

Drugs 130

pharmaphorum

OCTOBER 5, 2023

UK Biobank study “will shape drug discovery” Phil.

Biobanking 118

Biobanking Drugs 118

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Pharmaceutical Technology

OCTOBER 5, 2023

Forxiga has approval for adult use in 122 countries and in the EU to treat paediatric patients for T2D above the age of ten.

130

130

pharmaphorum

OCTOBER 5, 2023

How AI and omnichannel are transforming pharma marketing Mike.

Marketing 116

Marketing 116

Fierce Pharma

OCTOBER 5, 2023

The abrupt departure of Lonza’s CEO last month clearly hasn’t dampened the Swiss CDMO’s dealmaking prowess. | Lonza has extended a long-term collaboration with an unnamed “major global biopharmaceutical partner” to crank up commercial supply of antibody-drug conjugates at its site in Visp, Switzerland. The deal is set to boost Lonza’s current bioconjugation capacity fourfold, thanks to the addition of two new bioconjugation suites.

Antibody 116

Antibody Production Drugs 116

Pharmaceutical Commerce

OCTOBER 5, 2023

Panel discusses how digital transformation can best impact supply chains.

111

111

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials